DE60217357D1 - Verfahren zur bestimmung der wirkungen von botulinum-toxinen - Google Patents

Verfahren zur bestimmung der wirkungen von botulinum-toxinen

Info

Publication number
DE60217357D1
DE60217357D1 DE60217357T DE60217357T DE60217357D1 DE 60217357 D1 DE60217357 D1 DE 60217357D1 DE 60217357 T DE60217357 T DE 60217357T DE 60217357 T DE60217357 T DE 60217357T DE 60217357 D1 DE60217357 D1 DE 60217357D1
Authority
DE
Germany
Prior art keywords
determining
botulinum
toxines
effects
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60217357T
Other languages
English (en)
Other versions
DE60217357T2 (de
Inventor
M Holland
Edward Chow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of DE60217357D1 publication Critical patent/DE60217357D1/de
Application granted granted Critical
Publication of DE60217357T2 publication Critical patent/DE60217357T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE60217357T 2001-08-03 2002-08-02 Verfahren zur bestimmung der wirkungen von botulinum-toxinen Expired - Lifetime DE60217357T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30998801P 2001-08-03 2001-08-03
US309988P 2001-08-03
US10/208,165 US6984375B2 (en) 2001-08-03 2002-07-29 Nuclei density and nuclei area methods for determining effects of a botulinum toxin on muscles
US208165 2002-07-29
PCT/US2002/024478 WO2003015829A2 (en) 2001-08-03 2002-08-02 Methods of determining the effects of toxins

Publications (2)

Publication Number Publication Date
DE60217357D1 true DE60217357D1 (de) 2007-02-15
DE60217357T2 DE60217357T2 (de) 2007-11-15

Family

ID=26902958

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60217357T Expired - Lifetime DE60217357T2 (de) 2001-08-03 2002-08-02 Verfahren zur bestimmung der wirkungen von botulinum-toxinen

Country Status (7)

Country Link
US (3) US6984375B2 (de)
EP (1) EP1411991B1 (de)
JP (1) JP4214053B2 (de)
AT (1) ATE350067T1 (de)
DE (1) DE60217357T2 (de)
ES (1) ES2278965T3 (de)
WO (1) WO2003015829A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6859652B2 (en) 2000-08-02 2005-02-22 Mobile Satellite Ventures, Lp Integrated or autonomous system and method of satellite-terrestrial frequency reuse using signal attenuation and/or blockage, dynamic assignment of frequencies and/or hysteresis
US7792488B2 (en) 2000-12-04 2010-09-07 Atc Technologies, Llc Systems and methods for transmitting electromagnetic energy over a wireless channel having sufficiently weak measured signal strength
US6984375B2 (en) * 2001-08-03 2006-01-10 Allergan, Inc. Nuclei density and nuclei area methods for determining effects of a botulinum toxin on muscles
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
EP2015065B1 (de) 2006-04-28 2011-10-05 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Verfahren zur quantifizierung von neurotoxin
WO2009036334A1 (en) * 2007-09-14 2009-03-19 Corventis, Inc. Adherent multi-sensor device with empathic monitoring
US8506970B2 (en) * 2008-10-14 2013-08-13 Dt Scimed, Llc Dose and localization of botulinum toxins in skin and muscle
JP5703508B2 (ja) * 2009-07-09 2015-04-22 株式会社Ｕｂｅ科学分析センター 毒性試験法
CA2801421A1 (en) * 2010-06-11 2012-04-12 Synaptic Research, Llc N-end rule protease activity indication methods and uses thereof
ES2653249T3 (es) 2011-09-29 2018-02-06 Cellsnap, Llc Composiciones y métodos para ensayos de toxigenicidad
RU2704808C2 (ru) 2013-06-28 2019-10-31 Мерц Фарма Гмбх Энд Ко. Кгаа Средства и способы для определения биологической активности полипептидов нейротоксина в клетках
US20190030118A1 (en) * 2017-07-27 2019-01-31 Ipsen Biopharm Limited Treatment of lower limb spasticity
US11752335B1 (en) 2018-02-07 2023-09-12 Mary Kay Inc. Method for determining facial muscle responses

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5401243A (en) * 1990-08-21 1995-03-28 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US5183462A (en) * 1990-08-21 1993-02-02 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US5158976A (en) * 1990-10-29 1992-10-27 The Children's Medical Center Corporation Controlling glutamine/glutamate related neuronal injury
US6485413B1 (en) * 1991-04-29 2002-11-26 The General Hospital Corporation Methods and apparatus for forward-directed optical scanning instruments
US5548661A (en) * 1991-07-12 1996-08-20 Price; Jeffrey H. Operator independent image cytometer
US5314805A (en) * 1991-10-28 1994-05-24 Molecular Probes, Inc. Dual-fluorescence cell viability assay using ethidium homodimer and calcein AM
WO1994000481A1 (en) * 1992-06-23 1994-01-06 Associated Synapse Biologics Pharmaceutical composition containing botulinum b complex
US6309883B1 (en) * 1994-02-17 2001-10-30 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US6416959B1 (en) * 1997-02-27 2002-07-09 Kenneth Giuliano System for cell-based screening
DE69833059T3 (de) * 1997-07-15 2014-12-18 The Regents Of The University Of Colorado, A Body Corporate Verwendung von Botulinumtoxin zur Behandlung von Harninkontinenz
AU3748499A (en) * 1998-04-29 1999-11-16 Allergan, Inc. Compositions and methods for extending the action of clostridial neurotoxin
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6265379B1 (en) * 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US6429189B1 (en) * 1999-12-10 2002-08-06 Botulinum Toxin Research Associates, Inc. Cytotoxin (non-neurotoxin) for the treatment of human headache disorders and inflammatory diseases
US6143306A (en) * 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6337075B1 (en) * 2000-01-11 2002-01-08 Allergan Sales, Inc. Methods for treating diabetes
US6306403B1 (en) * 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
JP2004505278A (ja) * 2000-07-28 2004-02-19 シーワイティーワイシー　ヘルス　コーポレイション 乳管洗浄によって回収した乳管上皮細胞の細胞学的評価
US7273722B2 (en) * 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
WO2003000193A2 (en) * 2001-06-21 2003-01-03 Surromed, Inc. Covalent coupling of botulinum toxin with polyethylene glycol
AU2002318437A1 (en) * 2001-06-29 2003-03-03 Clinomics Biosciences, Inc. Evaluating neuropsychiatric diseases using a specimen-linked database
US6984375B2 (en) * 2001-08-03 2006-01-10 Allergan, Inc. Nuclei density and nuclei area methods for determining effects of a botulinum toxin on muscles

Also Published As

Publication number Publication date
EP1411991B1 (de) 2007-01-03
WO2003015829A3 (en) 2003-12-18
US7229605B2 (en) 2007-06-12
US20030026760A1 (en) 2003-02-06
US6984375B2 (en) 2006-01-10
JP2005509145A (ja) 2005-04-07
ATE350067T1 (de) 2007-01-15
US20050019338A1 (en) 2005-01-27
WO2003015829A2 (en) 2003-02-27
US20070218005A1 (en) 2007-09-20
ES2278965T3 (es) 2007-08-16
JP4214053B2 (ja) 2009-01-28
EP1411991A2 (de) 2004-04-28
DE60217357T2 (de) 2007-11-15

Similar Documents

Publication Publication Date Title
DE60217357D1 (de) Verfahren zur bestimmung der wirkungen von botulinum-toxinen
DK1796646T3 (da) Kosmetiske neurotoksinsammensætninger omfattende en botulinumtoksinbestanddel samt tilhörende fremgangsmåder
ATE255418T1 (de) Neurotoxine zur behandlung von pankreatischen krankheiten
DK0773788T3 (da) Forbedrede præparater og fremgangsmåder til kemodenervering under anvendelse af neurotoxiner
ATE535141T1 (de) Verfahren zur modifikation von pflanzlicher biomasse
DK0839006T4 (da) Fremgangsmåde til stabilisering af proteiner i et surt miljø med et højester-pectin
WO2006138059A3 (en) Treatment of autoimmune disorders with a neurotoxin
WO2004095176A3 (en) Detecting vulnerabilities in source code
DE60137331D1 (de) Verfahren zur abschätzung des ortes eines gerätes
MXPA06001173A (es) Metodo analitico para la pancreatina y composiciones comparables.
FR2708358B1 (fr) Procédé de saisie d'une information confidentielle, terminal et système de vérification associés.
DE60310400D1 (de) Botulinustoxine zur behandlung von priapismus
AU1985002A (en) Modified clostridial neurotoxins with altered biological persistence
ATE169171T1 (de) Verfahren zur erkennung von dienstwechselwirkungen in intelligenten netzwerken
DK0747471T3 (da) Proteasebehandlede og oprensede cellulase-sammensætninger samt fremgangsmåder til at reducere tilbagefarvning under enzymat
DE59711375D1 (de) Verfahren zur aktivierung von denaturiertem protein
ATE283286T1 (de) Adnf mischungen zur verbesserung der lernfähigkeit und der gedächtnisfunktion
DE60134657D1 (de) Phosphat-fluortenside zur verwendung in kohlendioxid
DE59009945D1 (de) Mittel zur hemmung von hiv-proteasen.
WO2005016233A3 (en) Botulinum neurotoxin b receptors and use thereof
ATE222883T1 (de) Verwendung von mannanases als schleimkontrollmittel
AU3162097A (en) Retinoid metabolizing protein
WO2002048352A1 (fr) Methode d'analyse d'expression genique
WO2004104826A3 (en) Method for disabling code functions based on date information
DE69434220D1 (de) Verfahren zur verhütung der nebenwirkungen und unempfindlichkeit gegenüber therapeutischen verwendungen von toxinen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition